Ovarian carcinoma (OC) is the most lethal gynecologic malignancy, accounting for over 180,000 deaths per year worldwide.[@bib1] OC is now recognized to comprise 5 core histologic subtypes: high-grade serous (HGS), endometrioid, clear cell, low-grade serous, and mucinous OC---each displaying distinct molecular landscapes and clinical behavior.[@bib2] Within HGS cases, homologous recombination deficiency by virtue of *BRCA1* or *BRCA2* mutation has been associated with favorable outcome, greater sensitivity to platinum-based chemotherapy, and marked benefit from poly (ADP-ribose) polymerase inhibitors.[@bib3], [@bib4], [@bib5], [@bib6] Conversely, *CCNE1* copy number gain has been associated with chemoresistance and poorer survival in this group.[@bib3], [@bib7]AJOG at a GlanceWhy was this study conducted?A number of investigators have reported a relatively indolent disease course in ovarian carcinoma patients experiencing isolated lymph node relapse. However, none have systematically compared these to extranodal relapse or performed molecular characterization of patients who go on to experience this distinct pattern of recurrence.Key findingsIsolated lymph node relapse patients demonstrated significantly prolonged overall and postrelapse survival compared with extranodal relapse cases. Isolated lymph node relapse cases demonstrated greater tumor-infiltrating lymphocyte burden at diagnosis, but did not demonstrate significant enrichment or depletion of *BRCA1/2* mutation or gain of *CCNE1*, both known to be prognostic in ovarian carcinoma.What does this add to what is known?This is the first report demonstrating significantly improved clinical outcome in isolated lymph node relapse ovarian carcinoma when compared directly with extranodal relapse, and represents the first study to perform molecular characterization of patients who go on to experience isolated lymph node relapse.

Though patients in most OC cases---particularly HGS OCs---are typically sensitive to chemotherapy in the first-line setting, the majority of patients will experience disease relapse, which acquires resistance to chemotherapy.[@bib8], [@bib9] The most common sites of recurrence are the pelvis and peritoneum.[@bib10] Involvement of lymph nodes (LNs) at relapse is common; however, recurrence confined solely to LNs is a rare event, accounting for ≤5% of relapsed OCs.[@bib11], [@bib12] These isolated LN relapse (ILNR) cases have been described as a unique clinical disease entity and are thought to experience a relatively indolent disease course, with a reported median postrelapse survival (PRS) and overall survival (OS) of around 2.5 to 4 years and \>5 years, respectively.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]

A number of previous studies have reported on the clinical outcome of apparent ILNR OC (summarized in [Table 1](#tbl1){ref-type="table"}).[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] Many of these studies have reported only a small number of cases,[@bib11], [@bib13], [@bib17], [@bib18] with a minority reporting larger numbers identified from multiple centers.[@bib14], [@bib16] To our knowledge, none of these studies have compared outcome directly to a matched extranodal relapse (ENR) cohort. Furthermore, they have not performed contemporary histologic subtyping or molecular characterization so as to identify potential subgroups of disease with a propensity to experience this distinct pattern of disease relapse.Table 1Previous reports of isolated lymph node relapse ovarian carcinomaILNR casesNFerrero[@bib16]Tu[@bib15]Gadducci[@bib14]Fotiou[@bib18]Legge[@bib12]Santillan[@bib17]Blanchard[@bib11]Uzan[@bib13]Summary7338692132252712Few reports of ≥40 casesAge at diagnosisYearsMedian 5424 (63%) \>50; 14 (37%) ≤50Median 58Mean 50Median 60Mean 58Mean 59Median 51Largely unremarkable compared with unselected OC cohortsRange29--7334--7836--6745--7641--8241-8542--71Stage at diagnosisI14 (19%)011 (16%)3 (14%)02 (8%)4 (15%)5 (42%)II4 (6%)15 (39%)6 (9%)3 (14%)1 (3%)5 (20%)5 (18%)1 (8%)III51 (70%)23 (61%)46 (67%)14 (67%)29 (91%)15 (60%)15 (56%)6 (50%)IV4 (6%)06 (9%)1 (5%)2 (6%)3 (12%)3 (11%)0RD following first-line debulking0 cm / \<0.5 cm57 (78%)17 (45%)22 (32%)8 (38%)14 (44%)18 (72%)NA7 (58%)≤1 cm10 (14%)10 (26%)11 (16%)7 (33%)6 (19%)5 (20%)NA4 (33%)\<2 cm4 (6%)11 (29%)36 (52%)4 (19%)0NA\>2 cm2 (3%)2 (10%)12 (38%)2 (8%)NA1 (8%)Grade at diagnosisI4 (6%)7 (18%)3 (4%)09 (32%)25 (100%) high gradeNANAII5 (7%)14 (37%)13 (19%)8 (38%)III64 (88%)17 (45%)54 (78%)13 (62%)19 (68%)NA\-\-\--4-Reported histologic subtype at diagnosisSerous53 (73%)19 (50%)52 (75%)16 (76%)26 (81%)19 (76%)17 (62%)[a](#tbl1fna){ref-type="table-fn"}8 (67%)Predominantly serous / HGS cases, as with unselected OC cohortsEndometrioid11 (15%)9 (24%)12 (17%)5 (24%)2 (6%)2 (8%)3 (11%)3 (25%)Clear cell001 (1%)0000Mucinous1 (1%)1 (3%)01 (3%)03 (11%)0Other8 (11%)9 (24%)4 (6%)3 (9%)4 (16%)4 (15%)1 (8%)DFI / time to ILNR[b](#tbl1fnb){ref-type="table-fn"}Median months181844 (62%)\
\>12 months2117.51626 months from diagnosis21Median 1.5--2 years DFIRange6--1929-968--1561--1346--401--1596--72ILNR site(s)Para-aortic only37 (51%)10 (26%)23 (33%)8 (38%)14 (44%)15 (60%)9 (33%) retro. alone, 6(22%) retro. + other. supraclavicular, mediastinal, iliac, and inguinal involvement in 7 (26%), 4 (15%), 4 (15%), and 3 (11%) cases5 (42%)Most commonly involves pelvic and/or para-aortic sitesPelvic only21 (29%)15 (39%)12 (17%)4 (19%)1 (3%)3 (12%)4 (33%)Para-aortic & pelvic9 (12%)7 (18%)6 (9%)4 (19%)9 (28%)1 (4%)1 (8%)Inguinal only3 (4%)2 (5%)12 (17%)4 (19%)2 (6%)5 (20%)1 (8%)Other combinations3 (4%)4 (11%)16 (23%)1 (5%)6 (19%)1 (4%)1 (8%)ILNR patternSingle region61 (84%)27 (71%)47 (77%)17 (81%)20 (63%)24 (96%)17 (63%)10 (83%)Most commonly localized to a single regionMultiregion12 (16%)11 (29%)14 (23%)4 (19%)9 (28%)1 (4%)10 (37%)2 (17%)NA\--8-3\-\--PRSMedian months5-y PRS 64%; 5-y OS ∼80%5-y PRS 66.5%32.1473737265-y PRS 71%Median 2--4 yearsOSMedian months62.9661096168Median \>5 yearsSurgery for ILNRYes73 (100%)19 (50%)24 (35%)21 (100%)12 (38%)25 (100%)8 (30%)12 (100%)Heterogeneous management, typically involving chemotherapyNo019 (50%)45 (65%)020 (63%)019 (70%)0ILNR intervention: regimeChemo alone05 (13%)44 (64%)019 (59%)08 (30%)0Surgery alone3 (4%)01 (1%)01 (3%)2 (8%)2 (7%)0Surgery-chemo combination70 (96%)19 (50%)22 (32%)17 (81%)11 (34%)15 (60%)5 (19%)10 (83%)Radio alone001 (1%)0002 (7%)0No intervention00001 (3%)07 (26%)0Other014 (37%)1 (1%)4 (19%)08 (32%)3 (11%)2 (17%)[^1][^2][^3][^4]

Here, we report clinical and molecular characterization of a matched ILNR and ENR cohort with contemporary pathology review to compare the clinical outcome and molecular landscape of ILNR and ENR OC.

Materials and Methods {#sec1}
=====================

Isolated lymph node relapse patient identification {#sec1.1}
--------------------------------------------------

ILNR OC cases were identified from the Edinburgh Ovarian Cancer Database ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Figure S1](#figS1){ref-type="fig"}), wherein the clinical variables, treatment details, and follow-up data of OC patients treated within the Edinburgh Cancer Centre are collected prospectively as part of routine care. Potential ILNR cases were identified using the search terms "lymph node" or "groin node" as the dominant site of relapse, yielding 161 results. Nonepithelial tumors (n = 1), tumors of borderline malignancy (n = 1), and primary LN serous carcinomas (n = 2) were excluded. Patients with concurrent extranodal disease (n = 50), lack of cross-sectional imaging to confirm sole ILNR (n = 13), or coexistence of other malignancies leading to uncertain origin of LN disease (n = 2) were excluded. Patients with residual disease (RD) after completion of first-line treatment (n = 19) or insufficient clinical data for eligibility assessment (n = 24) were also excluded, leaving 49 ILNR cases.

Matching of isolated lymph node relapse to extranodal relapse {#sec1.2}
-------------------------------------------------------------

ILNR cases were electronically matched to ENR cases with complete response to first-line therapy using the Edinburgh Ovarian Cancer Database. Matching criteria were as follows: (1) diagnostic histologic subtype and grade, (2) stage at diagnosis, (3) extent of RD following debulking surgery, and (4) closest age at diagnosis following matching of criteria 1--3. Criteria were relaxed to facilitate matching of all ILNR cases as detailed in [Supplementary Table S1](#tblS1){ref-type="table"} ([Appendix](#appsec1){ref-type="sec"}).

Ethical approval and tissue collection {#sec1.3}
--------------------------------------

Clinical research access and ethical approval for correlation of molecular data to clinicopathologic features and clinical outcome in OC was obtained via NHS Lothian Research and Development (reference ID 2007/W/ON/29). Ethical approval for the use of human tumor material in translational research was obtained from South East Scotland Human Annotated Bioresource (Lothian NRS Bioresource Ethics Reference 15/ES/0094-SR831). Tumor material was available for 75.5% (74 of 98) of cases (77.6%, 38 of 49 ILNR and 73.5%, 36 of 49 ENR).

Histologic subtyping of ovarian carcinomas {#sec1.4}
------------------------------------------

Contemporary pathology review of ILNR and matched ENR cases was performed by an expert gynecologic pathologist (C.S.H.). Where appropriate (n = 9), immunohistochemistry (IHC) for WT1 and p53 was performed to aid histologic subtyping.[@bib19] WT1 IHC was performed using 1:1000 dilutions of antibody M3561 clone 6F-H2 (Dako, Agilent Technologies, Santa Clara, CA). p53 staining was performed using 1:50 dilutions of antibody M7001 clone DO-7 (Dako, Agilent Technologies). Both stains were performed using the Leica Bond III Autostainer (Leica Biosystems, Milton Keynes, UK).

Nucleic acid isolation {#sec1.5}
----------------------

Up to 10 10-μm formalin-fixed paraffin-embedded sections, macrodissected using marked hematoxylin--eosin-stained slides as a guide to enrich for tumor purity ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Table S2](#tblS2){ref-type="table"}), were used for DNA extraction. DNA was extracted using the QIAamp DNA FFPE Tissue Kit and Deparaffinization Solution (Qiagen, Venlo, the Netherlands).

Panel-based sequencing of *BRCA* and non-*BRCA* homologous recombination deficiency genes {#sec1.6}
-----------------------------------------------------------------------------------------

High-throughput sequencing was performed using an 83-gene custom Integrated DNA Technologies gene capture panel with unique molecular indices, as described in the [Appendix](#appsec1){ref-type="sec"}. Gene targets, centered around the homologous recombination DNA repair pathway, are detailed in [Supplementary Table S3](#tblS3){ref-type="table"} ([Appendix](#appsec1){ref-type="sec"}). The median per-sample mean target coverage achieved was 386X.

Assessment of *CCNE1* copy number {#sec1.7}
---------------------------------

Copy number variants in *CCNE1* were characterized by TaqMan Genotyping qPCR Copy Number Assays (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA), as detailed in the [Appendix](#appsec1){ref-type="sec"}.

Assessment of tumor-infiltrating lymphocyte density {#sec1.8}
---------------------------------------------------

Tumor-infiltrating lymphocytes (TILs) were assessed using 4-μm FFPE sections of diagnostic tumor material from first-line cytoreductive surgery. IHC for CD3 and CD8 was performed using Bond ready-to-use CD8-4B11 and CD3-LN10 antibodies (Leica Biosystems) on the Leica Bond III Autostainer. Human tonsil was used as a positive control for both markers. Stained slides were digitized and marker-positive cells were quantified using QuPath[@bib20] in 8 randomly selected tumor-containing 500 × 500-μm fields per sample. Tumor area was marked as a region of interest ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Figure S2](#figS2){ref-type="fig"}) and marker-positive cells were quantified using the positive cell detection protocol as a percentage of the total cell number demonstrating marker positivity.

TIL scoring validation was performed by manual counting of marker-positive cells by 2 human observers (R.L.H. and A.H.P.), in a randomly selected validation cohort representing 15% of samples for each marker. The correlation of marker-positive cell counts (observer 1 vs observer 2 vs QuPath) demonstrated excellent agreement for both markers (Spearman's rho \> 0.95, *P* \< .0001 for all comparisons).

Statistical analyses {#sec1.9}
--------------------

Statistical analyses were performed using R version 3.5.1 (R Foundation, Vienna, Austria). Disease-free interval (DFI) was calculated as time from end of first-line chemotherapy to disease recurrence. Comparisons of OS and PRS were conducted using Cox proportional hazards regression models within the Survival R package[@bib21] and presented as hazard ratios (HRs) alongside their 95% confidence intervals (CIs). Frequency comparisons were made using the χ^2^ test and Fisher exact test as appropriate. Comparisons of TIL density were made using the Mann--Whitney *U* test. Analyses were adjusted for multiplicity of testing using the Bonferroni correction, where specified.

Results {#sec2}
=======

Cohort characteristics {#sec2.1}
----------------------

Demographics of the ILNR and ENR cohorts are summarized in [Table 2](#tbl2){ref-type="table"}. There was no significant difference in age at diagnosis, RD following primary surgical debulking, histology or grade of disease at diagnosis, or disease stage at diagnosis between the ILNR and ENR groups. These data indicate good fidelity of the ILNR--ENR matching process. Patterns of ILNR are described in [Table 3](#tbl3){ref-type="table"}.Table 2Demographics of isolated lymph node relapse and extranodal relapse ovarian carcinoma cohortsFactorClassILNR, n = 49ENR, n = 49ILNR vs ENRN%/rangeN%/range*P* valueStage at diagnosisI510.6510.21.000[a](#tbl2fna){ref-type="table-fn"}II1021.31122.4III2757.42857.1IV510.6510.2NA20Histology at diagnosisSerous2551.03367.3.502[b](#tbl2fnb){ref-type="table-fn"}Endometrioid1224.51122.5Clear cell12.012.0Mixed histology816.348.2Unclassified adenocarcinoma36.100.0Grade at diagnosisI00.012.01.000[c](#tbl2fnc){ref-type="table-fn"}II613.0612.2III4087.04275.7NA30Contemporary histologic classificationHGS3489.53186.1.733[d](#tbl2fnd){ref-type="table-fn"}Endometrioid25.338.3LGS25.312.8Mixed HGS / endometrioid00.01[∗](#tbl2fnlowast){ref-type="table-fn"}2.8No specimen available1113Surgical debulking statusRD \<2 cm3475.63370.2.733[e](#tbl2fne){ref-type="table-fn"}RD 2--5 cm715.6817.0RD ≥5 cm48.9612.8NA42First-line chemotherapyPlatinum2142.91734.7.693[f](#tbl2fnf){ref-type="table-fn"}Platinum combination2551.02857.1Other36.148.2Neoadjuvant first-line chemotherapyYes24.112.01.000[g](#tbl2fng){ref-type="table-fn"}No4795.94898.0Year of diagnosis≤19992346.92142.9.667[f](#tbl2fnf){ref-type="table-fn"}2000--20051938.82346.92006--2010714.3510.2Age at diagnosisMedian years6141-806241-80.339[h](#tbl2fnh){ref-type="table-fn"}Specimen from diagnosisPrimary site3391.72980.6.307[i](#tbl2fni){ref-type="table-fn"}Omentum25.6616.7Other12.812.8NA20No specimen available1113[^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16]Table 3Patterns of isolated lymph node relapse ovarian carcinomaCases (n)Proportion of cases (%)ILNR pattern Single-site2244.9 Multiregional 21734.7 3816.3 424.1ILNR sites Para-aortic only1632.7 Pelvic only48.2 Inguinal only24.1 Pelvic & para-aortic612.2 Supraclavicular and other sites612.2 Pelvic, para-aortic, and other(s)612.2 Other combinations918.4[^17][^18]

Clinical outcome in isolated lymph node relapse vs extranodal relapse {#sec2.2}
---------------------------------------------------------------------

ILNR patients displayed prolonged OS and PRS compared with the ENR cohort (HR = 0.55 \[0.34--0.87\], *P* = .011 and HR = 0.50 \[0.31--0.80\], *P* = .004) ([Figure 1](#fig1){ref-type="fig"}, A and [Figure 1](#fig1){ref-type="fig"}, B). The median OS and PRS in the ILNR cohort was 72.9 (95% CI 62.2--96.5) and 32.0 (95% CI 23.3--53.3) months, compared with 41.1 (95% CI 30.0--58.8) and 14.9 (95% CI 12.9--23.7) months in the ENR cohort. The length of the DFI prior to ILNR or ENR was not significantly different between the 2 cohorts (HR = 0.86 \[0.60--1.29\], *P* = .473).Figure 1Clinical outcome of isolated lymph node relapse OC**A,** Overall survival in ILNR vs ENR OC. **B,** Postrelapse survival in ILNR vs ENR OC. **C,** Postrelapse survival in ILNR OC by DFI length.*CI*, confidence interval; *DFI*, disease-free interval; *ENR*, extranodal relapse; *HR*, hazard ratio; *ILNR*, isolated lymph node relapse; *OC*, ovarian carcinoma.*Hollis et al. Clinical and molecular characterization of ILNR ovarian carcinoma. Am J Obstet Gynecol 2019*.

Multivariable analysis for OS accounting for extent of RD following primary debulking, FIGO stage, and age at diagnosis identified significantly prolonged OS in the ILNR cohort (HR^multi^ = 0.51 \[0.31--0.84\], *P* = .008) ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Table S4](#tblS4){ref-type="table"}). Multivariable analysis of PRS, accounting for DFI and age, identified prolonged PRS in ILNR cases (HR^multi^ = 0.52 \[0.33--0.84\], *P* = .007) ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Table S5](#tblS5){ref-type="table"}).

Significantly prolonged OS (HR^multi^ for OS = 0.53 \[0.29--0.99\], *P* = .046) and PRS (HR^multi^ for PRS = 0.54 \[0.31--0.96\], *P* = .037) was demonstrated for ILNR OC when HGS cases were considered specifically (34 ILNR HGS OCs, 31 ENR HGS OCs).

Longer disease-free interval is associated with prolonged postrelapse survival in isolated lymph node relapse ovarian carcinoma {#sec2.3}
-------------------------------------------------------------------------------------------------------------------------------

The importance of DFI on clinical outcome in ILNR OC remains controversial, with some authors reporting no association between DFI length and PRS or OS in this setting[@bib11], [@bib16], [@bib18] and others reporting significant associations.[@bib12], [@bib14], [@bib15] Within the ILNR cohort, DFI ≥12 months was associated with markedly prolonged PRS when accounting for patient age (HR^multi^ = 0.38 \[0.19--0.78\], *P* = .008), with median PRS of 47.3 months vs 20.1 months in those with DFI ≥12 months and DFI \<12 months, respectively ([Figure 1](#fig1){ref-type="fig"}, C).

Impact of isolated lymph node relapse pattern on outcome {#sec2.4}
--------------------------------------------------------

There was no clear differential PRS between multiregion ILNR and single-region ILNR (2 regions vs single-site HR = 1.06 \[0.49--2.30\], *P* = .890; ≥3 sites vs single-site HR = 0.94 \[0.36--1.43\], *P* = .898).

Six ILNR cases (12.2%) involved supraclavicular LN sites. Although these cases demonstrated an apparent trend for inferior PRS (HR = 2.52 \[0.95--6.69\], *P* = .064) ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Figure S3](#figS3){ref-type="fig"}), there was no significant difference after accounting for DFI and age (HR^multi^ = 1.63 \[0.58--4.60\], *P* = .359). Other specific LN sites were not associated with apparent differential PRS ([Appendix](#appsec1){ref-type="sec"}: [Supplementary Table S6](#tblS6){ref-type="table"}).

Molecular landscape of isolated lymph node relapse high-grade serous ovarian carcinoma {#sec2.5}
--------------------------------------------------------------------------------------

Sixty-four HGS OC cases (33 ILNR, 31 ENR) were successfully characterized for HR gene mutations and *CCNE1* copy number. Frequencies of genomic abnormalities are outlined in [Figure 2](#fig2){ref-type="fig"}, A and [Supplementary Table S3](#tblS3){ref-type="table"}. Within HGS OC cases, there was no significant difference in the rate of *CCNE1* copy number gain (18.2%, 6/33 vs 22.6%, 7/31, *P* = .900) or *BRCA1/2* mutation (24.4%, 8/33 vs 19.4%, 6/31, *P* = .865) between the ILNR and ENR cohorts ([Figure 2](#fig2){ref-type="fig"}, A).Figure 2Molecular landscape of isolated lymph node relapse and extranodal relapse ovarian carcinoma**A,** Genomic events in ILNR and ENR cases. **B,** Tumor-infiltrating lymphocyte burden of ILNR and ENR HGS ovarian carcinomas.*ENR*, extranodal relapse; *HGS*, high-grade serous; *ILNR*, isolated lymph node relapse; *LGS*, low-grade serous.*Hollis et al. Clinical and molecular characterization of ILNR ovarian carcinoma. Am J Obstet Gynecol 2019*.

The CD3+ and CD8+ TIL burden was greater in diagnostic tumor specimens from HGS OC patients who went on to experience ILNR when compared with their ENR counterparts (median CD3+ cell density 1.94% vs 1.13%, *P* = .001 and median CD8+ cell density 0.90% vs 0.45%, *P* = .009; Bonferroni-adjusted *P* = .003 and *P* = .019) ([Figure 2](#fig2){ref-type="fig"}, B).

Comment {#sec3}
=======

Principal findings {#sec3.1}
------------------

The principal findings of this study are as follows: (1) ILNR represents a distinct pattern of OC relapse with prolonged survival vs ENR cases; (2) longer DFI prior to ILNR is associated with prolonged PRS in ILNR; (3) ILNR OC do not demonstrate significantly differential composition of known genomic subtypes associated with prognosis, namely *BRCA1/2* mutation or gain of *CCNE1*; (4) cases that go on to experience ILNR demonstrate greater TIL burden at diagnosis compared with ENR cases.

Study strengths and limitations {#sec3.2}
-------------------------------

A key strength of this study is the direct comparison of ILNR OC with matched ENR cases: a number of studies have reported ILNR as a distinct pattern of OC relapse with a relatively indolent disease course but have not systematically compared ILNR cases directly to a matched ENR cohort.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] Moreover, these studies did not perform pathology review of identified cases, precluding the ability to characterize ILNR outcome in the context of contemporary OC histotypes, which are now known to display markedly differential clinical outcome.[@bib22] Critically, we characterize ILNR OC following contemporary histologic subtyping to facilitate investigation of ILNR in a histotype-specific manner.

The majority of previous studies investigating ILNR have identified fewer than 20 OC cases of serous histology that go on to experience this rare relapse pattern; moreover, previous reports have not performed molecular characterization of OC cases that demonstrate ILNR.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] We identified 49 ILNR OC patients treated within the Edinburgh Cancer Centre, including 34 cases reviewed as HGS OC. This study represents the largest ILNR OC series from a single center and the only report investigating the molecular landscape of ILNR OC to date.

Though this study does represent one of the largest reported ILNR OC cohorts, case numbers were still restricted owing to the rarity of ILNR OC. In particular, power to detect differential outcome between distinct patterns of ILNR was limited, and we could not perform meaningful analysis comparing rates of rare genomic events present in both ILNR and ENR cohorts, including mutational events in *RB1*, *NF1*, and *PTEN*, as well as gene-specific analysis of *BRCA1* and *BRCA2*. Other limitations of this study include heterogeneous treatment of OC patients across the time period in which these cases were diagnosed, though diagnosis periods were comparable between the ILNR and ENR cohorts ([Table 2](#tbl2){ref-type="table"}).

Clinical outcome in isolated lymph node relapse ovarian carcinoma {#sec3.3}
-----------------------------------------------------------------

The median PRS and OS of ILNR cases was approximately 2.7 and 6 years, consistent with previous reports of ILNR OC.[@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] ILNR cases displayed significantly prolonged OS and PRS compared to their ENR counterparts upon multivariable analysis (HR^multi^ = 0.51 and 0.52 for OS and PRS). Critically, this difference was maintained in a histotype-specific analysis of HGS cases, which account for the majority of OCs. To our knowledge, this is the first report directly demonstrating a significant difference in outcome between ILNR and ENR OC.

Only half of the reports investigating the impact of DFI length on ILNR outcome to date have identified associations with OS or PRS.[@bib12], [@bib14], [@bib15] Here, we demonstrate that DFI ≥12 months is associated with a substantial PRS benefit (median PRS approximately 3.9 vs 1.7 years), largely reflective of established associations in unselected OC cases.[@bib23] Although this contradicts reports from some investigators,[@bib11], [@bib16], [@bib18] 2 of these studies reported specifically in the context of ILNR undergoing secondary debulking[@bib16], [@bib18] and the other compared cases using a cut-off DFI of 24 months, rather than 12 months as described here,[@bib11] potentially explaining this discrepancy. Notably, the intervals considered in our study are akin to those used clinically to define platinum sensitivity in unselected relapsed OC.[@bib23]

We show no significant difference in clinical outcome between patients with ILNR at multiple sites vs those with single-site ILNR, or between distinct patterns of ILNR. Although univariable analysis suggested that supraclavicular LN involvement may confer inferior PRS, this trend was not apparent when accounting for DFI and patient age, suggesting that this is not a genuine phenomenon of supraclavicular ILNR. Notably, the number of patients with supraclavicular LN involvement was low (n = 6). Together, these data support the consideration of ILNR OC as a single disease entity, regardless of the number and location of involved sites.

The genomic landscape of isolated lymph node relapse ovarian carcinoma {#sec3.4}
----------------------------------------------------------------------

Until now, the molecular landscape of ILNR has been completely uncharacterized. It has therefore been unclear as to whether OC cases that go on to experience ILNR demonstrate enrichment of tumors belonging to known favorable genomic subgroups. Within unselected cohorts of HGS OC, inactivation of *BRCA1* or *BRCA2* has been associated with favorable outcome,[@bib3], [@bib4] while copy number gain of *CCNE1* has been associated with poor survival and chemoresistance.[@bib3], [@bib7] Genomic characterization of this cohort did not identify significant depletion or enrichment of these molecular events in ILNR HGS OC cases versus their ENR counterparts. These data suggest that the survival benefit of ILNR OC is not underpinned by large-scale enrichment for *BRCA1/2*-mutant cases with favorable prognosis or absence of *CCNE1*-gained cases that have poorer prognosis, and suggest that these genomic subgroups do not display markedly differential propensity for ILNR.

Greater tumor-infiltrating lymphocyte burden at diagnosis in patients who subsequently experience isolated lymph node relapse {#sec3.5}
-----------------------------------------------------------------------------------------------------------------------------

Intriguingly, assessment of the CD3+ and CD8+ cell burden in ILNR and ENR tumor material---reflective of whole T cell and cytotoxic T cell populations---uncovered significantly greater TIL burden in diagnostic tissue from patients who subsequently experienced ILNR (2-fold enrichment for CD8+ cells, approximately 1.7-fold enrichment for CD3+ cells). These data suggest that active engagement of the immune system at diagnosis impacts upon the nature of disease at relapse, and that immune-mediated control of cancer cells may contribute to the indolent disease course of ILNR OC. Indeed, these data may well be of interest in relation to the use of immune-directed therapies in cancer treatment.[@bib24], [@bib25] However, though many ILNR cases displayed high TIL burden, some cases demonstrated relatively low levels of TILs, alluding to mechanisms beyond effective T-cell engagement at diagnosis underpinning some ILNR cases.

Conclusion {#sec3.6}
----------

Collectively, the data presented here---supported by previous descriptions of apparent ILNR in the literature---demonstrate that ILNR represents a distinct pattern of OC with favorable clinical outcome when compared with ENR. Patients that go on to experience ILNR harbor greater TIL burden at diagnosis, but they do not show marked enrichment or depletion of known genomic subgroups associated with differential outcome.

Appendix {#appsec1}
========

Supplementary Figure S1Isolated lymph node relapse cohort identification from the Edinburgh Ovarian Cancer Database*Hollis et al. Clinical and molecular characterization of ILNR ovarian carcinoma. Am J Obstet Gynecol 2019*.Supplementary Figure S2Automated marker-positive cell quantification by QuPath*Hollis et al. Clinical and molecular characterization of ILNR ovarian carcinoma. Am J Obstet Gynecol 2019*.Supplementary Figure S3Postrelapse survival of isolated lymph node relapse ovarian carcinoma with and without supraclavicular lymph node involvement*Hollis et al. Clinical and molecular characterization of ILNR ovarian carcinoma. Am J Obstet Gynecol 2019*.Supplementary Table S1Tolerances for electronic matching of extranodal relapse to isolated lymph node relapseFeatureILNR OC case documented diagnostic characteristicMatched ENR OC case documented diagnostic characteristicPatientsStage at diagnosisInadequate information to stageStage II, n = 13Stage IIIC, n = 1Stage IIBStage IIA, n = 1Documented histology at diagnosisAdenocarcinomaSerous papillary, n = 39EndometrioidMixed serous/endometrioid, n = 1Mixed histologySerous papillary, n = 5Grade at diagnosisNAGrade I, n = 13Grade III, n = 2RD following debulking\<2 cmNA, n = 14NA2--5 cm, n = 1\>5 cm, n = 2[^19][^20][^21]Supplementary Table S2Cellularity of specimens used for DNA extractionTumor cellularity of macrodissected areaNumber (%) of cases\<20%3 (4.1%)20--39%7 (9.5%)40--59%9 (12.2%)60--79%26 (35.1%)≥80%29 (39.2%)[^22]Supplementary Table S3Frequency of patients with detrimental mutations in genes sequenced on Integrated DNA Technologies gene capture high throughput sequencing panelGeneILNR OC with mutationENR OC with mutation*ABCB1*10*ARID1A*12*ATM*20*ATR*10*BRCA1*63*BRCA2*33*CTNNB1*11*FANCC*01*KRAS*11*MSH2*11*NF1*41*PIK3CA*21*PRKDC*10*PTEN*11*RB1*31*SLX4*01*TP53*3231Genes with no detected mutations:\
*ATRX, BAP1, BARD1, BCL2L1, BLM, BRAF, BRIP1, C11orf65, CCNE1, CDK12, CHD4, CHEK1, CHEK2, EGFR, EMSY, ERBB2, ERCC4, EZH2, FANCA, FANCB, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GNAS, KIT, MAD2L2, MDM2, MLH1, MRE11, MSH6, MUS81, MUTYH, NBN, NDUFB2, NF2, NRAS, PALB2, PARP1, PARP2, PAXIP1, PDGFRA, PER3, PMS2, PPP2R1A, PPP2R2A, RAD50, RAD51, RAD51B, RAD51C, RAD54L, RNASEH2A, RNASEH2B, RNASEH2C, RPA1, RUNDC3B, SHFM1, SLC25A40, SLFN11, TOE1, TP53BP1, UBE2T, VRK2*[^23][^24]Supplementary Table S4Multivariable analysis for overall survival in isolated lymph node relapse vs extranodal relapse in ovarian carcinomaFactorClassNHR^multi^Lower 95% CIUpper 95% CI*P*Relapse typeILNR490.510.310.84.008ENR49RefRefRefRefStage at diagnosisEarly (I/II)310.410.171.02.055III550.450.191.03.060IV10RefRefRefRefNA2\-\-\--Surgical debulking statusRD \<2 cm670.600.321.12.109RD ≥2 cm25RefRefRefRefNA6\-\-\--Age at diagnosisYears1.031.001.05.050[^25][^26]Supplementary Table S5Multivariable analysis of time to isolated lymph node relapse as a predictor of postrelapse survival in isolated lymph node relapse ovarian carcinomaFactorClassNHR^multi^Lower 95% CIUpper 95% CI*P*Relapse typeILNR490.530.330.84.007ENR49RefRefRefRefDFI≥12 months460.470.290.75.006\<12 months52RefRefRefRefAgeYears1.031.011.06.006[^27][^28]Supplementary Table S6Univariable analyses of specific lymph node site involvement and association with postrelapse survivalFactorClassNHRLower 95% CIUpper 95% CI*P*Supraclavicular LN involvementYes62.520.956.69.064No43RefRefRefRefPelvic LN involvementYes200.730.351.51.393No29RefRefRefRefInguinal LN involvementYes90.720.281.87.502No40RefRefRefRefPara-aortic LN involvementYes361.100.482.56.818No13RefRefRefRef[^29][^30]
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